Forster, M. D., Forget, F., Murillo, S. M., García-Fructuoso, I., Ibrahim, N. K., Marathe, O., Kristensen, C. A., Laban, S., Metcalf, R., Majem, M., Peguero, J. A., Wildiers, H., Marmé, F., Braña, I., Mueller, C., Brignone, C., Triebel, F. (2026). Impact of eftilagimod alfa, an APC activator via MHC class II, on lymphocyte activation and survival outcomes in metastatic cancer patients.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.2569